A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa
Trial details
- Registry ID
- NCT07016750
- Drugs studied
- KB803
TrialRedline tracks 2 clinical trials sponsored by Krystal Biotech, Inc.: 2 Phase 3.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis BullosaNCT07016750 | KB803 | Recruiting | 2026-12Estimated |
| A Long-term Treatment With B-VEC for Dystrophic Epidermolysis BullosaNCT04917874 | Open Label Topical Beremagene Geperpavec (B-VEC) | Completed | 2023-07-31Actual |
Names as written in the registry records.
NCT07016750 · Krystal Biotech, Inc.
Before: 20 participants (planned). After: 16 participants (planned).
NCT07016750 · Krystal Biotech, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: To evaluate the safety and tolerability of KB803. Measure: To evaluate the effect of ophthalmic KB803 versus placebo on frequency of corneal. abrasion symptoms.. After: Measure: To evaluate the safety and tolerability of KB803. Measure: To evaluate the effect of ophthalmic KB803 on frequency of corneal abrasion symptoms..
Before: 16 participants (planned). After: 20 participants (planned).
Before: Mar 2026. After: Dec 2026.